The global intravenous immunoglobulin market was valued at USD 14.9 billion in 2025 and is expected to reach USD 16.0 billion in 2026, rising to USD 25.7 billion by 2033. The market is projected to expand at a 7.0% CAGR from 2026 to 2033. North America accounted for the largest revenue share at 45.9% in 2025, while Asia Pacific is anticipated to register the fastest growth during the forecast period.

Increasing demand for immunoglobulin-based therapies is being driven by the growing prevalence of autoimmune disorders, primary and secondary immunodeficiencies, and neurological diseases. Greater disease awareness, improved diagnosis, advances in immunotherapy, and an aging population are also supporting market expansion.

Key Market Trends & Insights

• Application: Immunodeficiency diseases represented the largest application segment, accounting for 19.5% of revenue in 2025.
• Distribution channel: Hospital pharmacies led distribution channels with a 57.1% revenue share in 2025.
• Regional leader: North America held the largest regional share at 45.9% in 2025.
• Fastest-growing region: Asia Pacific is expected to record the highest CAGR from 2026 to 2033.
• Leading country: The U.S. held the largest country-level market share in 2025.

Market Size & Forecast

Download a free sample report or claim your copy of this full market intelligence report

What Is Driving Demand for IVIG?

The increasing incidence of immune-related diseases is a major factor supporting demand for intravenous immunoglobulin therapies. IVIG remains an important treatment option for primary and acquired immunodeficiency diseases because of its established role in immune replacement therapy.

Awareness and advancements in immunotherapy are also contributing to market development. An aging population is particularly relevant because older individuals are more susceptible to immune-related conditions and chronic diseases requiring specialized treatment.

Lifestyle factors are another contributing element. Reduced physical activity and diets characterized by high levels of saturated fats, salt, sugar, and alcohol consumption are associated with a broader burden of lifestyle-related disorders, potentially increasing the need for healthcare interventions involving immune-related conditions.

Growing Recognition of Primary Immunodeficiencies

The substantial number of undiagnosed primary immunodeficiency cases represents an important opportunity for the intravenous immunoglobulin market. According to NCBI data, more than 6 million people worldwide were affected by primary immunodeficiencies in 2020, with approximately 70% to 90% of cases remaining undiagnosed.

More than 430 types of primary immunodeficiencies have been identified. These inherited disorders can increase susceptibility to infections and may also be associated with severe autoinflammation, autoimmunity, allergies, and malignancies.

Improved disease awareness and diagnosis, together with advances in plasma collection and manufacturing technologies, are expected to support the identification and treatment of additional eligible patients.

Cost and Accessibility Remain Major Challenges

Despite strong clinical demand, the high cost of IVIG treatment can restrict patient access and limit market expansion. IVIG infusions are commonly administered every 3 to 4 weeks, potentially requiring 12 to 16 treatments annually for long-term therapy.

The estimated IVIG price is approximately USD 73.89 per gram, while total treatment expenses can reach USD 10,000 or more, depending on disease severity. Immunoglobulin replacement therapy may continue for at least six months, creating a substantial financial burden for patients and healthcare systems.

According to the ABIM Foundation, annual IgG treatment costs can exceed USD 30,000. Consequently, affordability, reimbursement policies, and healthcare expenditure remain important factors affecting treatment accessibility.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Market Dynamics

Demand-Side Drivers

The market is supported by the increasing prevalence of:

• Primary immunodeficiency disorders
• Autoimmune diseases
• Neurological conditions
• Other diseases requiring immunoglobulin-based therapies

Growing disease awareness and improved diagnosis are expanding the pool of patients eligible for IVIG treatment. Use across hospitals and specialty care centers is also supporting demand.

Plasma Supply and Manufacturing

Because intravenous immunoglobulin products are derived from human plasma, market supply is closely linked to plasma collection, fractionation, and processing capacity. Manufacturers continue to invest in plasma collection networks and production infrastructure to address increasing treatment requirements.

A notable development occurred in June 2025, when Takeda received U.S. FDA approval for Gammagard Liquid ERC, a ready-to-use low-IgA immunoglobulin therapy for primary humoral immunodeficiency. The approval expanded Takeda's immunoglobulin portfolio and supported the availability of plasma-derived treatment options for eligible patients.

Regulatory and Reimbursement Factors

Product adoption is also influenced by regulatory requirements, reimbursement policies, healthcare spending, and treatment accessibility. These factors can affect both the availability of immunoglobulin therapies and the ability of patients and healthcare providers to sustain long-term treatment.

Regional Perspective

North America remained the leading regional market in 2025, accounting for 45.9% of global revenue. The region benefits from established healthcare infrastructure, high disease awareness, diagnostic capabilities, and access to specialized immunoglobulin therapies.

Asia Pacific is expected to experience the fastest growth from 2026 to 2033. Rising healthcare expenditure, improving diagnosis, increasing awareness of immunodeficiency and autoimmune diseases, and expanding healthcare infrastructure are expected to contribute to regional growth.

The U.S. held the largest country-level market share in 2025.

Competitive Landscape

Key companies profiled in the intravenous immunoglobulin market include:

• Biotest AG
• Baxter
• Octapharma AG
• LFB
• Grifols SA
• CSL
• China Biologics Products Inc.
• Kedrion
• BDI Pharma Inc.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Explore our dedicated business services:

• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.
• Prism AI: Market Intelligence with Cited Research -

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.